Why the study?
Does diabetes mellitus affect the 5-year clinical outcomes of CAD patients undergoing StentBoost-optimized PCI compared to non-diabetic patients?
Does diabetes mellitus affect the 5-year clinical outcomes of CAD patients undergoing StentBoost-optimized PCI compared to non-diabetic patients?
StentBoost-optimized PCI yields similar 5-year clinical outcomes in CAD patients regardless of diabetes status, with age and LVEF being the primary predictors of long-term outcomes.
Answers are grounded in this paper and cite their sources.
Supports similar long-term outcomes after StentBoost-optimized PCI regardless of diabetes; leaves open whether optimization neutralizes diabetes-related risk.
=0.02). A multivariate logistic regression analysis revealed that age and left ventricular ejection fraction rather than diabetes mellitus were independent predictors for long-term clinical outcomes. Conclusions StentBoost could effectively improve instant PCI results; the long-term clinical outcomes of StentBoost-optimized PCI were similar between diabetic and non-diabetic patients. Age and left ventricular ejection fraction were the independent predictors for long-term clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: